Table 7 Nonhaematologic toxicity

From: A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

 

Arm A

Arm B

Arm C

Arm D

 

All grades

Grade 3–4

All grades

Grade 3–4

All grades

Grade 3–4

All grades

Grade 3–4

Toxicity type

   

% of patients

   

Gastrointestinal origin

Diarrhoea

88

10

76

24

74

13

77

25

Nausea

73

15

73

5

65

9

80

23

Vomiting

54

10

57

3

50

9

59

16

Gastrointestinal pain

17

2

16

3

17

2

23

2

Anorexia

12

14

17

34

5

Other

        

Fatigue

51

7

38

3

61

4

52

7

Fever in absence of infection

12

2

19

-

15

4

16

Infection

7

2

11

5

11

11

7

Cholinergic syndrome

68a

41a

61a

2

7a

Alopecia

71b

43

67b

34b

  1. Toxicity is expressed as % of patients with adverse events possibly or probably related to study drug medication; worst grade during study. N=41 in arm A, 37 in arm B, 46 in arm C and 44 in arm D.
  2. aArm D is significantly different from arm A, B and C (P0.001).
  3. bArm D is significantly different from arm A and C (P<0.001).